Skip to main content

Table 1 Clinicopathological characteristics of the EAC study population with BE

From: LgR5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett's Esophagus?

Characteristics Patients
(n = 41)
LgR5
Barrett's esophagus*
p-value LgR5
Barrett's EAC
p-value
   low high   low high  
Age (y)     .100    .051
<66 21 (51%) 10 (48%) 11 (52%)   4 (19%) 17 (81%)  
≥66 20 (49%) 4 (20%) 16 (80%)   10 (50%) 10 (50%)  
Gender     .074    .673
Male 34 (83%) 14 (41%) 20 (59%)   11 (32%) 23 (68%)  
Female 7 (17%) 0 (0%) 7 (100%)   3 (43%) 4 (57%)  
Histological Grading     .305a    .083a
G1 11 (27%) 6 (55%) 5 (45%)   6 (55%) 5 (45%)  
G2 16 (39%) 5 (31%) 11 (69%)   6 (37%) 10 (63%)  
G3/4 14(34%) 3 (21%) 11 (79%)   2 (14%) 12 (86%)  
Depth of invasion     .481b    .155b
pT1 10 (24%) 4 (40%) 6 (60%)   6 (60%) 4 (40%)  
pT2 18 (44%) 7 (39%) 11 (61%)   6 (33%) 12 (67%)  
pT3 6 (15%) 1 (17%) 5 (83%)   1 (17%) 5 (83%)  
pT4 7 (17%) 2 (28%) 5 (72%)   1 (14%) 6 (86%)  
Lymph node metastases     .001    .0154
pN0 15 (37%) 10 (67%) 5 (33%)   9 (60%) 6 (40%)  
pN1-3 26 (63%) 4 (15%) 22 (85%)   5 (19%) 21 (81%)  
UICC stage     .481c    .155c
UICC I 9 (22%) 4 (44%) 5 (56%)   2 (22%) 4 (78%)  
UICC II 19 (46%) 7 (37%) 12 (63%)   7 (37%) 12 (63%)  
UICC III 13 (31%) 3 (23%) 10 (77%)   5 (15%) 11 (85%)  
UICC IV 0 (0%) 0 (0%) 0 (0%)   0 (0%) 0 (0%)  
Median OS (m) 42 m 32 (n = 14) 24 (n = 27)   33 (n = 14) 28 (n = 27)  
  1. Abbrevations: EAC, esophageal adenocarcinomas; BE, Barrett metaplasia; y, years; G, grading; UICC, International Union against Cancer; R, residual tumor; OS, overall survival; m, months. *Clinico-pathological features of BE are related to adjacent EAC.
  2. aG1/2 vs. GT3/4; bpT1/2 vs. pT3/4; cUICC I/II vs. UICC III/IV